Search research articles
Contact Us
Filters
Showing results (41-50 of 64) with videos related to
Page
of 7
Sort By:
Microbiology Spectrum
|
May 29, 2026
Comparative analysis of selective fungal culture media and incubation conditions for <i>Aspergillus fumigatus</i> in cystic fibrosis sputum
Gina Hong, Elisa M Vesely, Warda Memon, et al.
American Journal of Respiratory Cell and Molecular Biology
|
December 10, 2014
Antiinflammatory and Antimicrobial Effects of Thiocyanate in a Cystic Fibrosis Mouse Model
Joshua D Chandler, Elysia Min, Jie Huang, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
February 14, 2024
The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study
Scott H Donaldson, Timothy E Corcoran, Joseph M Pilewski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
November 22, 2024
What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study
Robin S Everhart, Emma McWilliams, Jill Maggs, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
August 21, 2025
"Time out for an hour, every day, my whole life": understanding treatment burden in cystic fibrosis in the era of Elexacaftor/Tezacaftor/Ivacaftor (ETI)
Jennifer L Butcher, Christopher Siracusa, Hannah Grabowski, et al.
Annals of the American Thoracic Society
|
February 10, 2018
Whole Blood Gene Expression Profiling Predicts Severe Morbidity and Mortality in Cystic Fibrosis: A 5-Year Follow-Up Study
Milene T Saavedra, Bradley S Quon, Anna Faino, et al.
The Journal of Clinical Investigation
|
March 28, 2023
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist
David P Nichols, Sarah J Morgan, Michelle Skalland, et al.
Annals of the American Thoracic Society
|
September 17, 2025
Long-term Reductions in Inflammation in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor
Scott D Sagel, T Spencer Poore, Brandie D Wagner, et al.
Plos One
|
September 13, 2011
Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR
Robert L Young, Kenneth C Malcolm, Jennifer E Kret, et al.
Contemporary Clinical Trials
|
November 18, 2024
Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study
Jill Maggs, Gregory S Sawicki, Callie Bacon, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 64) with videos related to
Sort By:
Page
of 7
Microbiology Spectrum
|
May 29, 2026
Comparative analysis of selective fungal culture media and incubation conditions for <i>Aspergillus fumigatus</i> in cystic fibrosis sputum
Gina Hong, Elisa M Vesely, Warda Memon, et al.
American Journal of Respiratory Cell and Molecular Biology
|
December 10, 2014
Antiinflammatory and Antimicrobial Effects of Thiocyanate in a Cystic Fibrosis Mouse Model
Joshua D Chandler, Elysia Min, Jie Huang, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
February 14, 2024
The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study
Scott H Donaldson, Timothy E Corcoran, Joseph M Pilewski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
November 22, 2024
What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study
Robin S Everhart, Emma McWilliams, Jill Maggs, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
August 21, 2025
"Time out for an hour, every day, my whole life": understanding treatment burden in cystic fibrosis in the era of Elexacaftor/Tezacaftor/Ivacaftor (ETI)
Jennifer L Butcher, Christopher Siracusa, Hannah Grabowski, et al.
Annals of the American Thoracic Society
|
February 10, 2018
Whole Blood Gene Expression Profiling Predicts Severe Morbidity and Mortality in Cystic Fibrosis: A 5-Year Follow-Up Study
Milene T Saavedra, Bradley S Quon, Anna Faino, et al.
The Journal of Clinical Investigation
|
March 28, 2023
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist
David P Nichols, Sarah J Morgan, Michelle Skalland, et al.
Annals of the American Thoracic Society
|
September 17, 2025
Long-term Reductions in Inflammation in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor
Scott D Sagel, T Spencer Poore, Brandie D Wagner, et al.
Plos One
|
September 13, 2011
Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR
Robert L Young, Kenneth C Malcolm, Jennifer E Kret, et al.
Contemporary Clinical Trials
|
November 18, 2024
Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study
Jill Maggs, Gregory S Sawicki, Callie Bacon, et al.
Page
of 7